BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 27597641)

  • 1. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases.
    Motamed N; Rabiee B; Poustchi H; Dehestani B; Hemasi GR; Khonsari MR; Maadi M; Saeedian FS; Zamani F
    Clin Res Hepatol Gastroenterol; 2017 Feb; 41(1):31-38. PubMed ID: 27597641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex differences in the impact of nonalcoholic fatty liver disease on cardiovascular risk factors.
    Du T; Sun X; Yuan G; Zhou X; Lu H; Lin X; Yu X
    Nutr Metab Cardiovasc Dis; 2017 Jan; 27(1):63-69. PubMed ID: 27956025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study.
    Lu ZY; Shao Z; Li YL; Wulasihan M; Chen XH
    World J Gastroenterol; 2016 Apr; 22(13):3663-9. PubMed ID: 27053858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.
    Motamed N; Sohrabi M; Ajdarkosh H; Hemmasi G; Maadi M; Sayeedian FS; Pirzad R; Abedi K; Aghapour S; Fallahnezhad M; Zamani F
    World J Gastroenterol; 2016 Mar; 22(10):3023-30. PubMed ID: 26973398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease.
    Zelber-Sagi S; Salomone F; Yeshua H; Lotan R; Webb M; Halpern Z; Santo E; Oren R; Shibolet O
    Liver Int; 2014 Jul; 34(6):e128-35. PubMed ID: 24118857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol efflux capacity is impaired in subjects with an elevated Fatty Liver Index, a proxy of non-alcoholic fatty liver disease.
    van den Berg EH; Gruppen EG; Ebtehaj S; Bakker SJL; Tietge UJF; Dullaart RPF
    Atherosclerosis; 2018 Oct; 277():21-27. PubMed ID: 30170220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study.
    Ren XY; Shi D; Ding J; Cheng ZY; Li HY; Li JS; Pu HQ; Yang AM; He CL; Zhang JP; Ma YB; Zhang YW; Zheng TZ; Bai YN; Cheng N
    Lipids Health Dis; 2019 Feb; 18(1):47. PubMed ID: 30744645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of gamma-glutamyl transferase as a suitable simple biomarker of the cardiovascular risk in children with non-alcoholic fatty liver disease.
    Bobrus-Chociej A; Flisiak-Jackiewicz M; Daniluk U; Wojtkowska M; Kłusek-Oksiuta M; Tarasów E; Lebensztejn D
    Acta Biochim Pol; 2018 Oct; 65(4):539-544. PubMed ID: 30380561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Under-prescription of statins in patients with non-alcoholic fatty liver disease.
    Del Ben M; Baratta F; Polimeni L; Pastori D; Loffredo L; Averna M; Violi F; Angelico F
    Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):161-167. PubMed ID: 27914698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of γ-glutamyl transferase levels in prediction of high cardiovascular risk among patients with non-alcoholic fatty liver disease.
    Kasapoglu B; Turkay C; Yalcın KS; Carlioglu A; Koktener A
    Indian J Med Res; 2016 Jan; 143(1):30-6. PubMed ID: 26997011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease (NAFLD) and the cardiovascular disease (CVD) risk categories in primary care: is there an association?
    Miptah HN; Ramli AS; Mohamad M; Hashim H; Tharek Z
    BMC Fam Pract; 2020 Nov; 21(1):238. PubMed ID: 33218301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remnant cholesterol, stronger than triglycerides, is associated with incident non-alcoholic fatty liver disease.
    Cheng Y; Zhang Q; Li H; Zhou G; Shi P; Zhang X; Guan L; Yan F; Xu C
    Front Endocrinol (Lausanne); 2023; 14():1098078. PubMed ID: 37214248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.
    Pursnani A; Massaro JM; D'Agostino RB; O'Donnell CJ; Hoffmann U
    JAMA; 2015 Jul; 314(2):134-41. PubMed ID: 26172893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
    Alkassabany YM; Farghaly AG; El-Ghitany EM
    Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease.
    Pisetta C; Chillè C; Pelizzari G; Pigozzi MG; Salvetti M; Paini A; Muiesan ML; De Ciuceis C; Ricci C; Rizzoni D
    High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):321-330. PubMed ID: 32436128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study.
    Nass KJ; van den Berg EH; Faber KN; Schreuder TCMA; Blokzijl H; Dullaart RPF
    Metabolism; 2017 Jul; 72():37-46. PubMed ID: 28641782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis.
    Morrison AE; Zaccardi F; Khunti K; Davies MJ
    Liver Int; 2019 Mar; 39(3):557-567. PubMed ID: 30358050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Risk for Cardiovascular Events in Patients with Diabetic Kidney Disease and Non-Alcoholic Fatty Liver Disease.
    Chinnadurai R; Chrysochou C; Kalra PA
    Nephron; 2019; 141(1):24-30. PubMed ID: 30384370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cardiovascular risk assessment tools and their guidelines in evaluation of 10-year CVD risk and preventive recommendations: A population based study.
    Motamed N; Rabiee B; Perumal D; Poustchi H; Miresmail SJ; Farahani B; Maadi M; Saeedian FS; Ajdarkosh H; Khonsari MR; Hemasi GR; Zamani F
    Int J Cardiol; 2017 Feb; 228():52-57. PubMed ID: 27863362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.